Coronary artery disease and depression: Possible role of brain-derived neurotrophic factor and serotonin transporter gene polymorphisms

International Journal of Molecular Medicine

Volumn 24, Issue 6, 2009, Pages 813-818

  Bozzini, Sara ^a   Gambelli, Patrick ^a   Boiocchi, Chiara ^a   Schirinzi, Sandra ^a   Falcone, Rossana ^a   Buzzi, Paola ^a   Storti, Cesare ^b   Falcone, Colomba ^a,b,c  

^a UNIVERSITY OF PAVIA   (Italy)

^b University and Research Hospital   (Italy)

^c IRRCS Gruppo San Donato   (Italy)

Author keywords

Brain derived neurotrophic factor; Coronary artery disease; Depression; DNA polymorphisms; Serotonin

Indexed keywords

ALANINE; BRAIN DERIVED NEUROTROPHIC FACTOR; GLYCINE; LEUCINE; METHIONINE; SERINE; SEROTONIN TRANSPORTER; VALINE;

ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEPRESSION; DISEASE ASSOCIATION; DNA FLANKING REGION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; SEROTONIN UPTAKE;

BRAIN-DERIVED NEUROTROPHIC FACTOR; CHI-SQUARE DISTRIBUTION; COMORBIDITY; CORONARY ARTERY DISEASE; DEPRESSION; FEMALE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; QUESTIONNAIRES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 70350772544     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000297     Document Type: Article

References (48)

1. Penninx BW, Beekman AT, Honig A, Deeg DJ, Schoevers RA, van Eijk JT and van Tilburg W: Depression and cardiac mortality: results from a community based longitudinal study. Arch Gen Psychiatry 58: 221-227, 2001.
2. Joynt KE, Whellan DJ and O'Connor CM: Depression and cardiovascular disease: mechanisms of interaction. Biol Psychiatry 54: 248-261, 2003.
3. Lewin GR and Berde YA: Physiology of the neurotrophins. Annu Rev Neurosci 19: 289-317, 1996.
4. Kermani P and Hempstead B: Brain-derived neurotrophic factor: a newly described mediator of angiogenesis. Trends Cardiovasc Med 17: 140-143, 2007.
5. Ejiri J, Inoue N, Kobayashi S, et al: Possible role of brain-derived neurotrophic factor in the pathogenesis of coronary artery disease. Circulation 112: 2114-2120, 2005.
6. Ventriglia M, Bocchio Chiavetto L, Bonvicini C, Tura GB, Bignotti S, Racagni G and Gennarelli M: Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer's disease. Mol Psychiatry 7: 136-137, 2002.
7. Momose Y, Murata M, Kobayashi K, Tachikawa M, Nakabayashi Y, Kanazawa I and Toda T: Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann Neurol 51: 133-136, 2002.
8. Sen S, Nesse R, Stoltenberg S, et al: A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. Neuropsychopharmacology 28: 397-401, 2003.
9. Neves-Pereira M, Mundo E, Muglia P, King N, Macciardi F and Kennedy JL: The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am J Hum Genet 71: 651-655, 2002.
10. Egan MF, Kojima M, Callicott JH, et al: The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112: 257-269, 2003.
11. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF and Weinberger DR: Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 23: 6690-6694, 2003.
12. Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL and Lee FS: Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wildtype BDNF in neurosecretory cells and cortical neurons. J Neurosci 24: 4401-4411, 2004.
13. Chen ZY, Ieraci A, Teng H, et al: Sortilin controls intracellular sorting of brain-derived neurotrophic factor to the regulated secretory pathway. J Neurosci 25: 6156-6166, 2005.
14. Artigas F: Serotonin receptors: role in depression. Actas Esp Psiquiatr 36: 28-30, 2008.
15. Pazos A, Probst A and Palacios JM: Serotonin receptors in the human brain-IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 21: 123-139, 1987.
16. Marek GJ: Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 28: 402-412, 2003.
17. Marek GJ: The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluorexetine. Neuropsychopharmacology 30: 2205-2215, 2005.
18. Yu B, Becnel J, Zerfaoui M, Rohatgi R, Boulares AH and Nichols CD: Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency. J Pharmacol Exp Ther 327: 316-323, 2008.
19. Heils A, Teufel A, Petri A, Stober G, Riederer S, Bengel D and Lesch KP: Allelic variation of human serotonin transporter gene expression. J Neurochem 66: 2621-2624, 1996.
20. Delbruck SJ, Wendel B and Grunewald I: A novel allelic variant of the human serotonin transporter gene regulatory polymorphism. Cytogenet Cell Genet 79: 214-220, 1997.
21. Murakami F, Shimomura T, Kotani K, Ikawa S, Nanba E and Adachi K: Anxiety traits associated with a polymorphism in the serotonin transporter gene regulatory region in the Japanese. J Hum Genet 44: 15-17, 1999.
22. Narita N, Narita M, Takashima S, Nakayama M, Nagai T and Okado N: Serotonin transporter gene variation is a risk factor for sudden infant death syndrome in the Japanese population. Pediatrics 107: 690-692, 2001.
23. Lesch KP, Bengel D, Heils A, et al: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527-1531, 1996.
24. Lopez AD, Mathers CD, Ezzati M, Jamison DT and Murray CJ: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367: 1747-1757, 2006.
25. McCaffery JM, Pogue-Geile MF, Ferrell RE, Petro N and Manuck SB: Variability within alpha- and beta-adrenoreceptor genes as a predictor of cardiovascular function at rest and in response to mental challenge. J Hypertens 20: 1105-1114, 2002.
26. Fuster V, Gotto AM, Libby P, Loscalzo J and McGill HC: 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 1. Pathogenesis of coronary disease: the biologic role of risk factors. J Am Coll Cardiol 27: 964-976, 1996.
27. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H and Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 97: 1837-1847, 1998.
28. Severus WE, Littman AB and Stoll AL: Omega-3 fatty acids, homocysteine, and the increased risk of cardiovascular mortality in major depressive disorder. Harv Rev Psychiatry 9: 280-293, 2001.
29. Zigelstein RC, Bush DE and Fauerbach JA: Depression, adherence behavior, and coronary disease outcomes. Arch Intern Med 158: 808-809, 1998.
30. Gottlieb SS, Khatta M, Friedmann E, et al: The influence of age, gender, and race on the prevalence of depression in heart failure patients. J Am Coll Cardiol 43: 1542-1549, 2004.
31. Sullivan M, Simon G, Spertus J and Russo J: Depression-related costs in heart failure care. Arch Intern Med 162: 1860-1866, 2002.
32. Rozanski A, Blumenthal JA and Kaplan J: Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 99: 2192-2217, 1999.
33. Musselman DL, Evans DL and Nemeroff CB: The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 55: 580-592, 1998.
34. Schins A, Honig A, Crijns H, Baur L and Hamulyak K: Increased coronary events in depressed cardiovascular patients: 5-HT2A receptor as missing link? Psychosom Med 65: 729-737, 2003.
35. Hofer M, Pagliusi SR, Hohn A, Leibrock J and Barde YA: Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO J 9: 2459-2464, 1990.
36. Castren E, Thoenen H and Lindholm D: Brain-derived neurotrophic factor messenger RNA is expressed in the septum, hypothalamus and in adrenergic brain stem nuclei of adult rat brain and is increased by osmotic stimulation in the paraventricular nucleus. Neuroscience 64: 71-80, 1995.
37. Fujimura H, Altar CA, Chen R, et al: Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 87: 728-734, 2002.
38. Donovan MJ, Lin MI, Wiegn P, et al: Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development 127: 4531-4540, 2000.
39. Erasmus RT: The brain and heart: dancing in unison? Clin Chim Acta 400: 1-2, 2009.
40. Gopalakrishnan P, Ragland MM and Tak T: Gender differences in coronary artery disease: review of diagnostic challenges and current treatment. Postgrad Med 121: 60-68, 2009.
41. Shaw LJ, Miller DD, Romeis JC, Kargl D, Younis LT and Chaitman BR: Gender differences in the noninvasive evaluation and management of patients with suspected coronary artery disease. Ann Intern Med 120: 559-566, 1994.
42. Krumolz HM, Douglas PS, Lauer MS and Pasternak RC: Selection of patients for coronary angiography and coronary revascularization early after myocardial infarction: is there evidence for a gender bias? Ann Intern Med 116: 785-790, 1992.
43. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders: 4th edition, American Psychological Association, Washington DC, 1994.
44. Goggi J, Pullar IA, Carney SL and Bradford HF: Modulation of neurotransmitter release induced by brain-derived neurotrophic factor in rat brain striatal slices in vitro. Brain Res 941: 34-42, 2002.
45. Cerrito F, Lazzaro MP, Gaudio E, Arminio P and Aloisi G: 5HT2-receptors and serotonin release: their role in human platelet aggregation. Life Sci 53: 209-215, 1993.
46. Eddahibi S, Humbert M, Fadel E, et al: Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108: 1141-1150, 2001.
47. Nagatomo T, Rashid M, Abul Muntasir H and Komiyama T: Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther 104: 59-81, 2004.
48. Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ and Chesebro JH: Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation 82: II47-II59, 1990.